The role of von Willebrand factor in determining the risk of ischemic stroke in Hawler city: a case-control study

Sazgar Anwar Hameed; Salar Adnan Ahmed

doi:10.15218/zjms.2018.016

Authors

Sazgar Anwar Hameed Hawler Teaching Hospital, Erbil, Iraq.
Salar Adnan Ahmed Department of Clinical Biochemistry, College of Medicine, Hawler Medical University, Erbil, Iraq.

DOI:

https://doi.org/10.15218/zjms.2018.016

Keywords:

Ischemic stroke, von Willebrand factor, Lipid profile

Abstract

Background and objective: Ischemic stroke is classically characterized as a neurological deficit attributed to an acute focal injury of the central nervous system by a vascular cause, it occurs as a result of obstruction by a blood clot (thrombus) or plugs within a blood vessel supplying blood to the brain. In this study, we investigated the association of von Willebrand factor-antigen and serum lipids with ischemic stroke.

Methods: The following retrospective study was conducted on 138 participants; 88 patients with ischemic stroke and 50 healthy controls.

Results: In crude analyses, Plasma von Willebrand factor antigen, fasting serum Total cholesterol, Triglycerides and LDL-C were significantly higher in patients with ischemic stroke than in controls (P <0.001, P <0.001, P = 0.003, P <0.001, respectively), while the difference in the level of serum HDL-C between patients with ischemic stroke and control was significantly lower (P = 0.023).

Conclusion: These data suggest that von Willebrand factor, total cholesterol, triglycerides, LDL-C and HDL-C gives some contribution to stroke risk even in the elderly and that von Willebrand factor antigen and lipid profile assessment must be taken into account in estimating the individual risks of stroke.

Metrics

Metrics Loading ...

References

Mazya MV. Intracerebral hemorrhage in patients treated with intravenous thrombolysis for acute ischemic stroke. M.Sc. thesis in clinical neuroscience. Karolinska Institute.Stockholm. Sweden; 2014.

Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de Maat MP, et al. High von Willebrand Factor Levels Increase the Risk of Stroke The Rotterdam Study. Stroke 2010; 41: 2151-6.

Harikumar K, Abdul Althaf S, Kishore KB, Ramunaik M, Suvarna CH. A Review on Hyperlipidemic. IJNTPS 2013; 3(4):59-70.

Hamad WA. Effect of atorvastatin with or without ezetimibeon serum lipid profile and ALT in hyperlipidemic patients. M.Sc. thesis in clinical biochemistry. College of Medicine. Hawler Medical University; 2009.

Murray RK, Granner DK, Mayes PA, Rodwell VW. Harper's illustrated biochemistry. 26thed.USA: Appleton and Lange; 2003.

Ruggeri ZM, Ware J. The structure and function of von Willebrand factor.ThrombHaemost1992; 67:594-9.

Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. ClinChem 1974; 20 (4):470-5.

Tietz NW. Text book of clinical chemistry. 3rd ed.Burtis:Ashwood, WB Saunders; 1999.

Beth D, Robert G, Trap P. Research questions about two separate or independent groups. In:asic and clinical biostatics. Singapore: McGraw-Hill Higher education; 2001.

Wannamethee SG, Whincup PH, Lennon L, Rumley A, Lowe GD. Fibrin D-Dimer, Tissue-Type Plasminogen Activator, von Willebrand Factor, and Risk of Incident Stroke in Older Men. Stroke 2012; 43:1206-11.

De Meyer SF, Stoll G, Wagner DD, Kleinschnitz CH. von Willebrand Factor: An Emerging Target in Stroke Therapy. Stroke 2012; 43:599-606.

Van schie MC, De Maat MP, Dippel DW, De Groot PG, Lenting PJ, Leebeek FW, et al. von Willebrand factor propeptide and the occurrence of a first ischemic stroke. J Thromb Haemost 2010; 8:1424-6.

Hanson E, Jood K, Karlsson S, Nilsson S, Blomstrand C, Jern C. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost 2011; 9:275-81.

Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Garcia EB, et al. High von Willebrand Factor Levels Increase the Risk of First Ischemic Stroke: Influence of ADAMTS13, Inflammation, and Genetic Variability. Stroke 2006; 37:2672-7.

Chaudhury SR, GhoshS, Kar D. Comparative lipid profile study between ischemic and hemorrhagic stroke. J Chem Pharm Res 2014; 6(11):20-7.

Sreedhar K, Srikant B, Joshi L, Usha G. Lipid profile in non-diabetic stroke – a study of 100 cases. J Assoc Physicians India 2010; 58:547-51.

Togha M, Gheini MR, Ahmadi B, Khashaiar P, Razeghi S. Lipid profile in cerebrovascular accidents. Ir J neurol 2011; 10(2):1-4.

Shilpasree AS, Sahukar S, Murthy J, Kumar K. A study of serum apolipoprotein A1, apolipoprotein B and lipid profile in stroke. J Clin Diagn Res 2013; 7(7):1303-6.

Garcia SG, Concepcion OF, Carriera RF, Sainz CM, Maza J, Monteagudo AG, et al. Association between blood lipids and types of stroke. MEDICC Rev 2008; 10(2):27-32.

Koren-Morag N, Goldbourt U, Graff E, Tanne D. Apolipoproteins B and A1 and the risk of ischemic cerebrovascular events in patients with preexisting atherothrombotic disease. J Neurol Sci 2008; 270:82-7.

Malek R, Hoque M, Shaha PR, Hossain S, Ahmed A, Akhter M.Association of Apo B, Apo A1 and lipid Profile with Early Onset Stroke. J Bangladesh Soc Physiol 2015; 10(2):51-5.

Liu XN, GaoY, Ye J, Wang DW, Liao YH, Ma AQ, et al. Association of small, dense low density lipoprotein with stroke. Zhonghua Yi Xue Za Zhi 2003; 83(22):1939-42.

Soyama Y, Miura K, Morikawa Y, Nishijo M, Nakanishi Y, Naruse Y, et al. High density lipoprotein cholesterol and risk of stroke in Japanese men and women: The Oyabe study. Stroke 2003; 34(4):863-8.

Philip-Ephraim EE, Charidimo A, Williams UE, Otu AA, Eyong KI, EphraimRP. Serum Lipid Profile In Ischemic Stroke Patients in Southern Nigeria. IOSR-JDMS 2015; 14(5):72-4.

Kostulas K. Genetic analysis of Ischemic Stroke and predisposing carotid artery stenosis. M.Sc. thesis in clinical neuroscience. Karolinska Institute. Stockholm. Sweden;2007.

Voet D, Voet JG. Biochemistry. 2nd ed. USA: John Wiley & Sons; 1995.

Mathews CK, van Holde KE, Ahern KG. Biochemistry. 3rd ed.USA: Addison Wesley Longman; 2000.

Adibhatla RM, Hatcher JF. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2010; 12(1):126-9.